CY3B.F · Adamis Pharmaceuticals Corporation

-

Please sign in to comment on CY3B.F

1 Comment

Admin

4 years ago

Adamis Pharmaceuticals Corporation is currently in a long term uptrend where the price is trading 13.4% above its 200 day moving average.

From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.6.

Adamis Pharmaceuticals Corporation's total revenue sank by 27.1% to $4M since the same quarter in the previous year.

Its net income has dropped by 6.9% to $-7M since the same quarter in the previous year.

Finally, its free cash flow fell by 33.4% to $-6M since the same quarter in the previous year.

Based on the above factors, Adamis Pharmaceuticals Corporation gets an overall score of 2/5.

Exchange	F
CurrencyCode	EUR
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
ISIN	US00547W2089

Market Cap	122K
PE Ratio	None
Dividend Yield	0.0%
Beta	1.22
Target Price	None

ABOUT

Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injectable pre-filled single dose syringe products for use in the emergency treatment of acute allergic reactions comprising anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was founded in 2006 and is headquartered in San Diego, California.

CY3B.F · Adamis Pharmaceuticals Corporation

-

Adamis Pharmaceuticals Corporation

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Adamis Pharmaceuticals Corporation using a moving average strategy